MICS IOL modification does not affect PCO

Article

Modifying a MICS IOL from a 3-piece to a 1-piece haptic design does not cause any significant changes in PCO amount.

Modifying a MICS IOL from a 3-piece to a 1-piece haptic design does not cause any significant changes in PCO amount, according to recently produced data.

A research team led by Dr Birgit Weingessel, Department of Ophthalmology, Hietzing Hospital, Vienna, Austria, studied 80 eyes of 40 patients with age-related cataract.

Each participant received a 1-piece MICS IOL in one eye and a 3-piece MICS IOL in the other. After one year of follow-up patients were assessed using a slit-lamp. High-resolution images were taken to determine PCO amount and visual acuity was measured accordingly.

Mean regeneratory PCO score and the neodymium-yttrium-aluminium-garnet laser capsulotomy rate were significantly low for both IOLs. But capsular folds occurred more often in the eyes that were administered the 3-piece IOL.

The abstract can be found in the January edition of the British Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.